<DOC>
	<DOCNO>NCT02138357</DOCNO>
	<brief_summary>The primary objective study determine whether Butrans Transdermal System ( BTDS ) reduce RLS symptom severity patient moderate severe idiopathic RLS naïve opiate treatment . The secondary objective study investigate effect BTDS mood , sleep , quality life . The study consist nine visit . Depending need medication titration , may also two schedule telephone contact . Visit 1 : This screen visit determine study eligibility . Eligible subject choose participate must undergo medication washout describe detailed protocol visit 1 2 . Treatment period # 1 ( Visits 2 - 5 ; day 0 - 28 ) : Baseline measure record subject randomize treatment order visit 2 ( day 0 ) . Study medication well rescue medication ( l-dopa , non-blinded active treatment use within limited dose range describe detailed protocol ) dispense . Subjects begin treatment period # 1 immediately . The study medication titrate within allow range accord subject 's report symptom visit 3 ( day 7 ) , visit 4 ( day 14 ) , telephone contact ( day 21 ) . Visit 5 occur day 28 include assessment outcome measure first treatment period . Visit 5 also mark begin second treatment period . Treatment period # 2 ( Visits 6 - 8 ; day 28 - 56 ) : Procedures similar describe treatment period # 1 . Visit 8 mark end second treatment period outcome measure ascertain . Follow visit ( Visit 9 ; day 70 ) : This safety follow-up visit approximately two week visit 8 review adverse event .</brief_summary>
	<brief_title>Butrans Treatment Restless Legs Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Subject diagnosis RLS , define International Restless Legs Study Group ( IRLS ) essential criterion : An urge move leg , usually accompany cause uncomfortable unpleasant sensation leg . The urge move unpleasant sensation begin worsen period rest inactivity lie sit . The urge move unpleasant sensation partially totally relieved movement , walk stretch , least long activity continue . The urge move unpleasant sensation worse even night day occur even night . Subject moderate severe RLS symptom , define International Restless Legs Scale ( IRLS ) score great equal to15 baseline visit ( visit 2 ) . Subject RLS symptom , opinion investigator , require roundtheclock treatment . Subject speak read English . Subject able provide inform consent . Subject age ≥25 ≤75 . Subject BMI ≥18 ≤35 Subject naïve opioid treatment , defined subject receive ≥5 mg oxycodone past 14 day history daily use ≥5 mg oxycodone equivalent past 3 month . If subject currently treat RLS , s/he must inadequate response intolerant current , nonopioid regimen . If subject currently treat RLS , s/he must contraindication history intolerance nonopioid treatment option RLS , concern side effect option , preference nonoral medication . If subject currently treat medication RLS , washout period least 3 day require ( 5 halflives longeracting agent ) . Subject 's history and/or clinical record document change medication active central nervous system ( antidepressant , analgesic , antipsychotic , antiepileptic , hypnotic , etc . ) least 30 day prior visit 1 . Subject able understand study procedures agree remain stable medication period study . Women childbearing potential must agree use medically accept method birth control . Acceptable form birth control include : Condom + spermicide Diaphragm + spermicide Oral contraceptive pill , hormone implant ( like Norplant ) , injection ( like DepoProvera ) Intrauterine Device Lifetime history DSMIVopiod , alcohol , substance abuse . History opioid treatment RLS inadequate response Positive urine toxicology screen visit 1 . Another chronic pain syndrome would , opinion investigator , interfere evaluation RLS symptom response study medication . Plan undergo procedure may require short longterm opiates pain control course trial . History severe mental illness . Women pregnant , lactating , plan become pregnant . Shift work commitment allow regular sleep night . Known hypersensitivity intolerance opioids . History Long QT Syndrome immediate family member condition , know prolongation QTc interval . QTc interval prolongation &gt; 500 m screen EKG Visit 1 . History malignant melanoma . Current use monoamine oxidase inhibitor . Prior current clinically significant impulse control disorder , determine clinical interview Modified Minnesota Impulse Disorders Interview Visit 1.8 Untreated severe sleep apnea , define AHI &gt; 30 . Iron deficiency , define ferritin &lt; 15 Visit 1 . Any dermatologic condition result widespread compromise skin integrity , define &gt; 50 % surface area within 8 site describe BTDS application . Current use class IA class III antiarrhythmic medication . Significant risk suicide clinical interview . Known hypersensitivity buprenorphine excipient BTDS . Current unstable medical illness . Any medical psychiatric condition , opinion investigator , would interfere participation study .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Restless Legs Syndrome</keyword>
	<keyword>Willis Ekbom Disease</keyword>
	<keyword>Twitchy Legs</keyword>
	<keyword>Periodic Limb Movements</keyword>
	<keyword>Leg Movements</keyword>
	<keyword>Augmentation</keyword>
	<keyword>Requip</keyword>
	<keyword>ropinirole</keyword>
	<keyword>Mirapex</keyword>
	<keyword>pramipexole</keyword>
	<keyword>gabapentin</keyword>
	<keyword>Horizant</keyword>
	<keyword>Neupro</keyword>
	<keyword>rotigotine</keyword>
</DOC>